Incipient and Subclinical Tuberculosis: Defining Early Disease States in the Context of Host Immune Response

被引:87
作者
Achkar, Jacqueline M. [1 ]
Jenny-Avital, Elizabeth R. [1 ]
机构
[1] Albert Einstein Coll Med, Div Infect Dis, Dept Med, Bronx, NY 10461 USA
关键词
HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED PATIENTS; COMMERCIAL URINARY LIPOARABINOMANNAN; PULMONARY TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS; LATENT TUBERCULOSIS; UNDIAGNOSED TUBERCULOSIS; ANTIRETROVIRAL THERAPY; DIAGNOSTIC-ACCURACY; CHEST RADIOGRAPH;
D O I
10.1093/infdis/jir451
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Latent Mycobacterium tuberculosis infection (LTBI) and active tuberculosis (TB) are 2 ends of a spectrum of states ranging from asymptomatic infection to overt disease. While progressing from LTBI to TB, patients often undergo asymptomatic states with detectable manifestations indicative of disease. Such asymptomatic disease states frequently remain undiagnosed, and their manifestations and duration are mostly dependent on host immune response. Various terms referring to such states are used in the literature, often interchangeably and without explicit definitions. Defining these intermediate states in concrete terms is important for pragmatic reasons, as they might impact upon the diagnostic performance of TB biomarkers and could also present targets for therapeutic interventions. We here propose definitions for 2 commonly used terms, "incipient" and "subclinical" TB, to describe asymptomatic disease states occurring at opposite ends of the host response spectrum. We propose using the term "incipient TB" when referring to early, contained disease in asymptomatic, relatively immunocompetent persons. In contrast, we propose using the term "subclinical TB" to refer to disease in asymptomatic, immunocompromised individuals in whom it is largely associated with loss of effective containment. The rationale for this article is to facilitate the discussion of such early disease states, especially in relation to their impact on TB biomarker discovery and assessment of new diagnostics, and with regard to treatment decisions and ultimately outcome.
引用
收藏
页码:S1179 / S1186
页数:8
相关论文
共 87 条
[31]   Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management [J].
Gardam, MA ;
Keystone, EC ;
Menzies, R ;
Manners, S ;
Skamene, E ;
Long, R ;
Vinh, DC .
LANCET INFECTIOUS DISEASES, 2003, 3 (03) :148-155
[32]  
Gennaro ML, 2007, INT J TUBERC LUNG D, V11, P624
[33]  
GIRLING DJ, 1989, AM REV RESPIR DIS, V139, P871
[34]   Significance of abnormal chest radiograph findings in patients with HIV-1 infection without respiratory symptoms [J].
Gold, JA ;
Rom, WN ;
Harkin, TJ .
CHEST, 2002, 121 (05) :1472-1477
[35]   ACTIVE PULMONARY TUBERCULOSIS IN PATIENTS WITH AIDS - SPECTRUM OF RADIOGRAPHIC FINDINGS (INCLUDING A NORMAL APPEARANCE) [J].
GREENBERG, SD ;
FRAGER, D ;
SUSTER, B ;
WALKER, S ;
STAVROPOULOS, C ;
ROTHPEARL, A .
RADIOLOGY, 1994, 193 (01) :115-119
[36]   Effect of HIV status on chest radiographic and CT findings in patients with tuberculosis [J].
Haramati, LB ;
JennyAvital, ER ;
Alterman, DD .
CLINICAL RADIOLOGY, 1997, 52 (01) :31-35
[37]   The Likelihood of an Indeterminate Test Result from a Whole-Blood Interferon-γ Release Assay for the Diagnosis of Mycobacterium tuberculosis Infection in Children Correlates With Age and Immune Status [J].
Haustein, Thomas ;
Ridout, Deborah A. ;
Hartley, John C. ;
Thaker, Urvashi ;
Shingadia, Delane ;
Klein, Nigel J. ;
Novelli, Vas ;
Dixon, Garth L. J. .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2009, 28 (08) :669-673
[38]   RELATIONSHIP OF THE MANIFESTATIONS OF TUBERCULOSIS TO CD4 CELL COUNTS IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
JONES, BE ;
YOUNG, SMM ;
ANTONISKIS, D ;
DAVIDSON, PT ;
KRAMER, F ;
BARNES, PF .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1993, 148 (05) :1292-1297
[39]   Subclinical tuberculosis: A new entity? [J].
Jones-Lopez, EC ;
Ellner, JJ ;
Whalen, CC .
CLINICAL INFECTIOUS DISEASES, 2005, 41 (07) :1069-1070
[40]   Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent [J].
Keane, J ;
Gershon, S ;
Wise, RP ;
Mirabile-Levens, E ;
Kasznica, J ;
Schwieterman, WD ;
Siegel, JN ;
Braun, MM .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (15) :1098-1104